872044-70-7

Basic information

• Product Name: AN-0128
• Synonyms: AN-0128;ZTLSOLUCMQEGEA-UHFFFAOYSA-N
• CAS NO: 872044-70-7
• Molecular Formula: C20H16BCl2NO3
• Molecular Weight: 400.06294
• Mol File: 872044-70-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AN-0128(CAS DataBase Reference)
• NIST Chemistry Reference: AN-0128(872044-70-7)
• EPA Substance Registry System: AN-0128(872044-70-7)

Safety Data

• Hazardous Substances Data: 872044-70-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
AN-0128 is used as an anti-inflammatory agent for the treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. It works by inhibiting Janus kinase (JAK) enzymes, which play a role in the inflammatory process, leading to a reduction in skin inflammation and improved symptoms.
Used in Dermatology:
AN-0128 is used as a topical treatment for inflammatory skin conditions. Its application helps to reduce the production of inflammatory cytokines, leading to decreased skin inflammation and improved symptoms. The favorable safety profile and good efficacy demonstrated in clinical trials make it a promising option for patients suffering from these conditions.

Upstream product

• 515157-47-8 B,B-bis(3-chloro-4-methylphenyl)borinic acid 
• 874-24-8 3-hydroxypyridine-2-carboxylic acid 
• 83846-48-4 3-chloro-4-methyliodobenzene 

Relevant articles and documents

Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome

The NLRP3 inflammasome is an important regulator of the sterile inflammatory response, and its activation by host-derived sterile molecules leads to the intracellular activation of caspase-1, processing of the pro-inflammatory cytokines interleukin-1β (IL-1β)/IL-18, and pyroptotic cell death. Inappropriate activation of NLRP3 drives a chronic inflammatory response and is implicated in several non-communicable diseases, including gout, atherosclerosis, type II diabetes and Alzheimer's disease. In this study, we report the design, synthesis and biological evaluation of novel boron compounds (NBCs) as NLRP3 inflammasome inhibitors. Structure–activity relationships (SAR) show that 4-fluoro substituents on the phenyl rings retain NLRP3 inhibitory activity, whereas more steric and lipophilic substituents diminish activity. Loss of inhibitory activity is also observed if the CCl3 group on the oxazaborine ring is replaced by a CF3 group. These findings provide additional understanding of the NBC series and will aid in the development of these NLRP3 inhibitors as tool compounds or therapeutic candidates for sterile inflammatory diseases.

PROCESS FOR MANUFACTURING PICOLINATE BORINIC ESTERS

The present invention relates to the field of boron-containing compounds, particularly boron compounds and pharmaceutical compositions thereof that exhibit with antibacterial and/or anti-inflammatory activities, and uses thereof. Methods for preparing and

Topical formulations of borinic acid antibiotics and their methods of use

Disclosed are topical formulations, for example, creams, gels, or lotions, of borinic acid antibiotic compounds active against acne vulgaris or secondarily infected skin conditions.

Identification of a novel boron-containing antibacterial agent (AN0128) with anti-inflammatory activity, for the potential treatment of cutaneous diseases

A series of borinic acid picolinate esters were synthesized and screened for their minimum inhibitory concentration (MIC) against Gram-positive and -negative bacteria. Our lead compounds were then screened for anti-inflammatory activity. From these studie

Anti-viral uses of borinic acid complexes

Compositions and methods of use of borinic acid complexes, especially hydroxyquinoline, imidazole and picolinic acid derivatives, as anti-viral agents as well as therapeutic agents for the treatment of diseases caused by viruses are described.

ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES

Compositions and methods of use of borinic acid complexes, especially hydroxyquinoline, imidazole and picolinic acid derivatives as anti-parasitic agents as well as therapeutic agents for the treatment of diseases caused by parasite are described.

BORON-CONTAINING COMPOUNDS AND METHODS OF USE

Methods of treating and/or preventing surface infections, such as acne, in an animal, such as a human being, using antibiotics incorporating borinic acid complexes, especially picolinic acid derivatives, are disclosed, along with compositions of these ant